My name is Jason Gerberry. I'm one of the SMID cap biotech and specialty pharma analysts. And so pleased to be introducing our next company presenter, Teva Pharmaceuticals and Richard Francis, CEO.

We couldn't find what you’re looking for right now ...

Teva is poised to benefit from rising demand for generic drugs due to a favorable macro and political environment. The company's valuation is attractive despite its high debt load, which it is ...

By Sarah Maslin Nir The agency cited Teva’s continuing supply problems as well as those of other drug makers struggling to fill the gap. By Christina Jewett If finalized, the agreement ...

After opting out of Teva’s $4.25 billion national opioid settlement last year, the city of Baltimore has secured its own payout through a settlement deal worth $80 million. Teva will make an ...

Courts have split over whether the statute of repose runs from the date of the last alleged misstatement or from each alleged ...

Teva's long haul to a turnaround of its business has been dealt a blow by the FDA, which has just declined to approve the company's long-acting formulation of schizophrenia drug risperidone. The ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...